KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 5,104 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 5,104 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $50,121.28. Following the sale, the chief executive officer now owns 278,855 shares of the company’s stock, valued at $2,738,356.10. This trade represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

KalVista Pharmaceuticals Stock Up 9.5 %

KALV stock opened at $10.71 on Thursday. The company’s 50-day moving average price is $8.80 and its two-hundred day moving average price is $10.43. The firm has a market cap of $529.27 million, a P/E ratio of -2.94 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. Equities analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. TD Cowen initiated coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Bank of America started coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target on the stock. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals has an average rating of “Buy” and a consensus target price of $23.80.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Suvretta Capital Management LLC lifted its position in shares of KalVista Pharmaceuticals by 16.6% during the 4th quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company’s stock worth $41,613,000 after buying an additional 701,007 shares during the last quarter. Tang Capital Management LLC lifted its holdings in shares of KalVista Pharmaceuticals by 13.2% in the fourth quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company’s stock worth $41,451,000 after acquiring an additional 572,300 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its holdings in shares of KalVista Pharmaceuticals by 32.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock worth $41,400,000 after acquiring an additional 1,200,000 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of KalVista Pharmaceuticals by 19.3% in the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company’s stock valued at $40,402,000 after purchasing an additional 770,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of KalVista Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock valued at $19,102,000 after purchasing an additional 104,716 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).